A to Z / Cognitive

Davunetide

Also known as NAP, AL-108, CP201.

Best known for The neuroprotective peptide that reached a phase 2/3 trial, and what its results teach

Evidence★★★☆☆

Safety dataModerately characterised

Route Nasal · injectable

United StatesInvestigational; phase 2/3 primary endpoints not met

AustraliaNot approved

as at 16 September 2026

What it is and what it does

Davunetide is an eight-amino-acid fragment of activity-dependent neuroprotective protein (ADNP), developed as a treatment for neurodegenerative disease. It reached phase 3, where it did not meet its primary endpoint.

It is included in this book for what its research programme teaches: it is the cognitive peptide that was carried all the way to a large, well-designed trial, and that trial gave a clear answer.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with Cerebrolysin, Semax, P21, Dihexa

Related entries

CerebrolysinThe brain peptide mixture used clinically outside the West · Evidence ★★★☆☆
SemaxThe leading nootropic peptide · Evidence ★★☆☆☆
P21The neurogenesis peptide from Alzheimer's research · Evidence ★☆☆☆☆
DihexaThe Alzheimer's research peptide at an early stage of study · Evidence ★☆☆☆☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about Davunetide. It is not medical advice and not a recommendation to use it.